IGF-Ⅱ SILENCING INHIBITED HEPG2 CELL PROLIFERATION AND PROMOTING ANOIKIS
Elevated expression of insulin-like growth factor-Ⅱ (IGF-Ⅱ) is a frequent genetic abnormality seen in hepatocellular carcinoma (HCC). For a better understanding of its role in maintaining the malignant phenotype, we examined the antiproliferation and anti-anoikis effects elicited by a decrease in the transcription and protein levels of IGF-Ⅱ by RNAi in HepG2 cells. Real-time qPCR analysis shown that transfection of siRNA targeting IGF-Ⅱ was 85. 3％ at mRNA and 75％ at protein levels. Transfected with miRNA-IGF-Ⅱ significantly decreased cell proliferation (P<0. 05) and rendered cells sensitive to anoikis (P < 0. 01), Indicating that the expression of IGF-Ⅱ is associate with proliferation and the transformed phenotype of HCC cells in vitro, suggesting a promising strategy for targeted therapy in HCC and forming a basis for future in vivo trials.
HCC IGF- Ⅱ RNAi targeted therapy
Yao Ninghua Yao Dengfu Xu Wei Chen Jie Yu Dandan
Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nanjing, China
国际会议
重庆
英文
316-318
2011-10-28（万方平台首次上网日期，不代表论文的发表时间）